US/UK/Canada

Share

Contacts

  • Ulf Hannelius

    CEO


    Box 7349, SE-103 90 Stockholm
    +46 8 661 00 26
    +46 8 661 63 68
    https://www.diamyd.com

    • Links

    Quotes

    The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.
    Ulf Hannelius, CEO
    Our top strategic priority is to prepare for a marketing application for Diamyd®
    Ulf Hannelius, CEO
    Pick a time period -
    Tags ( Active)

    Results from the EDCR IIa trial where Diamyd® is given subcutaneously

    30-month results from EDCR IIa, an investigator initiated pilot trial in which the diabetes vaccine Diamyd® is given subcutaneously combined with etanercept and vitamin D, show that the treatment is safe and tolerable. No serious side effects have been reported. As expected, based on previously reported 15-month results, the results at 30 months show no clear positive effect on the clinical course of the disease.When all 20 patients had been followed for 30 months in the EDCR IIa trial, endogeonus insulin production (measured as stimulated C-peptide) had decreased on average by 70% and

    Diamyd® subcutaneously continues to show weaker results than when administered intralymphatically

    A preliminary 15-month interim report from EDCR IIa, an investigator initiated pilot trial where the diabetes vaccine Diamyd® is administered subcutaneously in combination with etanercept and vitamin D shows,  when all 20 patients have been followed for fifteen months, that the treatment is safe and tolerable. No serious side effects have been reported. Results pertaining to the patients’ own insulin production, HbA1c and external insulin requirements are, however, weaker in EDCR IIa than from the ongoing DIAGNODE-1 trial where the diabetes vaccine is administered directly into the lymphnode.

    Diamyd® in combination with etanercept and vitamin D shows safety after six months

    Diamyd Medical today announced that a first six-month interim report from EDCR IIa, a clinical researcher-initiated pilot trial in which the diabetes vaccine Diamyd® is combined with the immunosuppressive drug etanercept and vitamin D, when all 20 patients have been followed for six months, preliminary shows that the treatment is safe and tolerable. No serious side effects have been reported. Professor Johnny Ludvigsson, principal investigator and sponsor for the study will present the 6-month-results tomorrow Saturday, May 20, at the Scandinavian Society for the Study of Diabetes meeting

    Diamyd® in combination with etanercept and vitamin D shows safety in a first preliminary interim report

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that a first six-month interim report comprising five patients in EDCR IIa, a pilot researcher-initiated clinical study in which the diabetes vaccine Diamyd® is combined with two other already approved agents, the immunosuppressive drug etanercept and vitamin D, preliminary shows the treatment is safe and tolerable. No serious side effects have been reported. This is the first time that this combination of agents is tested against the complex autoimmune process that causes type 1 diabetes.EDCR IIa (Etanercept-

    Diamyd Medical plans first interim report from open label pilot study EDCR IIa with the diabetes vaccine Diamyd® in the first quarter of 2016

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that a first six month interim report comprising five patients treated with etanercept and the diabetes vaccine Diamyd® is intended to be presented during the first quarter of 2016. The study is open labeled, meaning not placebo-controlled, and is conducted at nine pediatric diabetes clinics in Sweden. Professor Johnny Ludvigsson, Linköping University is principal investigator and sponsor of the study.EDCR IIa is an open label trial, where Diamyd® is combined with etanercept and vitamin D. The trial comprises 20

    New concept with the Diamyd® diabetes vaccine approved for testing in children and adolescents with type 1 diabetes

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that the Swedish Medical Products Agency has approved another new researcher-initiated combination study with the Diamyd® diabetes vaccine. In the study, Diamyd® will be combined with two other agents – vitamin D and the immunosuppressive drug etanercept. This is the fourth researcher-initiated clinical trial with the Diamyd® diabetes vaccine to receive regulatory approval this autumn. Two other clinical studies with the diabetes vaccine are already ongoing.This is the first time that this combination of agents is tested

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media